Form 4: Cadrenal Therapeutics Insider Sells Shares

Quang X. Pham, Director and Officer of Cadrenal Therapeutics, Inc., reported the sale of 3,613 shares of common stock on June 16, 2026, and 513 shares on June 17, 2026, under a Rule 10b5-1 trading plan.

Summary

• Quang X. Pham, who holds positions as Director, 10% Owner, and Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc., has reported transactions involving the sale of company stock.
• On June 16, 2026, Mr. Pham sold 3,613 shares of common stock at a weighted average price of $3.18 per share. This sale was conducted under a Rule 10b5-1 trading arrangement.
• On June 17, 2026, an additional 513 shares of common stock were sold at a weighted average price of $3.16 per share, also pursuant to the Rule 10b5-1 plan.
• Following these transactions, Mr. Pham directly beneficially owns 128,589 shares of common stock.
• Additionally, 200,000 shares are held indirectly through The PVBQ Living Trust, where Mr. Pham serves as Trustee and has sole voting and dispositive power, with his child as the sole beneficiary.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing neutrally as it reports routine insider sales conducted under a pre-established trading plan, which mitigates concerns about opportunistic selling.

Negatives

• Insider selling activity, particularly by a key executive and director, can sometimes be perceived negatively by the market, although in this case, it was conducted under a pre-arranged trading plan.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan is a common strategy for executives to sell shares without facing accusations of insider trading, providing a pre-determined schedule or set of conditions for sales.

Stakeholder Impact

• Shareholders may observe insider selling, but the use of a Rule 10b5-1 plan suggests these sales were pre-planned and not necessarily indicative of negative sentiment towards the company's future prospects.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Sale, Rule 10b5-1, Cadrenal Therapeutics, Quang X. Pham, Beneficial Ownership, Common Stock